Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Saw these 43% up on this site *( D ) not showing as a riser on table , made me wonder if I did hold .
There is hope for my 80% losing positions .
This news must of been known to any big boys before today's RNS .
News today.
C4X receives USD11 million from AstraZeneca following NRF2 trials
C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.
The Manchester, England-based drug discovery company received USD11.0 million from the Cambridge, England-based pharmaceutical maker AstraZeneca.
The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November.
In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.
C4X Chief Executive Officer Clive Dix said: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation. We believe that our unique approach can deliver transformative oral therapies for patients suffering from immuno-inflammatory diseases. This is a great start to our year and we are confident of seeing further progress across our entire portfolio in 2024."
Shares in C4X were up 12% at 10.00 pence each in London on Wednesday morning.
By Hugh Cameron, Alliance News reporter
Runway was already to Dec 24 and now extended to around Sept 2025, even without any further milestone payments or a sale of the non-core Malt-1 asset (both of which are expected).
Mcap now around 30m. Morphic whose only asset is in the same space as ONE of C4XD's (and looking inferior in phase 1 trials due to the worryingly high dose required) has a market cap of $1.44 billion.
This has been floating under the radar for far too long.
All (unwarranted) funding worries now pushed out to ridiculous time horizons and CD has already said that it's entirely possible that the company is now self financing. There's really no reason for this not to fly much higher after the initial wave of profit taking.
I know the company gives interviews on proactive so would expect one there at least.
The share needs to be promoted. Vox Markets might be a start as Vox has done wonders for the likes of Destiny Pharma. There's no point in being a success if hardly anyone knows about it. Come on Clive et al get out there and tell the market the great story and prospects to come.
The market potential in immuno-inflammation is large and growing, reflecting the need for better treatments. With a robust balance sheet, focused strategy and streamlined portfolio, we believe we are strongly positioned in immuno-inflammation and excited about the future.
On the out-licensed programme, the company noted that Sanofi is making progress on the IL-17A inhibitor programme for inflammatory diseases towards the next milestone.
Of its portfolio of early-stage discovery immuno-inflammatory molecules, the board still anticipates moving two projects into lead optimisation by the end of 2024, following the project initiation process assessment involving C4X’s proprietary platforms, Conformetrix and PatientSeek, together with a thorough analysis of the commercial viability.
PatientSeek was launched in February to optimise patient selection, with the potential to match the most effective treatments with groups of patients who are most likely to benefit thereby ensuring the right drug is given to the right patient, based on their genetics.
Only 12.8p to buy and a market cap of only 25 million with the potential to get 400 million dollars, well im in but am i missing something.
Neil is just another sad troll with nothing better to do. Suspect he may be posting as firestarter on advfn who does the same on any shares that issue good news and see material gains.
Bloody hell Neil, you are one miserable git, every share that rises you are there with your doom and gloom posts. The 3 ghosts didn’t come to see you on Christmas Eve then?
Morning Neil, nice to see you bringing cheer and goodwill to the board lol. Have a look at this though and do some analysis and I think you’ll agree it’s significantly undervalued. After the results just before Christmas one analyst firm gave the SP a target of 55p which might seem a tad extreme at present but there is ample room for growth from here. I don’t think this is a share for day traders though
Niel you sorry excuse for a human. Dropped by to pish on another good story. You seem to pop up anywhere with a rise to spread your tosh.
Well done anyone holding around 8p but the usual suspects who bought at 14p expecting more are already 10% and a 10% spread so will be left holding this when it drops back towards 10p
The positive update on AZ milestone payment confirms C4XD has the product delivery portfolio that major players are very attracted to and can support with significant investments in to C4XD portfolio, should see Sanofi milestone payment coming to follow this great news.
I recall Panmure target is significantly higher that current share price.
C4X Discovery should attract more investors now, but let’s hope the directors give more interviews and shout out their success. My past concern is that while they have done great work they seem to hide their light under a bushel
Excellent RNS and good to see a significant chunk of non-dilutive funding. From memory cash burn last year was around £15m and during this financial year C4x have now received just under £25m through milestones and sale of the Orexin-1 programme. The licensing agreement for the NRF2 Activator programme was signed just over a year ago and it's obviously performing well in preclinical development at AstraZeneca.
More importantly, today's RNS is great validation of C4x's ability to successfully develop small molecule drugs in the hot field of immuno/inflammatory diseases and bodes well for the rest of the pipeline. There are a handful of underappreciated UK bios quietly going about their business without resorting to they hype of others and way below the radar of most AIM investors. It's brilliant to see them progress.
C4XD must be close to updating market on their Sanofi agreement next....
12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that its subsidiary, C4X Discovery Limited (“C4XD”, “C4X Discovery” or the “Company”), has signed an exclusive worldwide licensing agreement with Sanofi (NASD: SNY, PAR: SAN – “Sanofi “), worth up to €414 million, for C4XD’s oral pre-clinical IL-17A inhibitor programme. Under the terms of the agreement, C4XD will receive an upfront payment of €7 million and could receive up to a further €407 million in potential development, regulatory and commercialisation milestones, of which €11 million is in pre-clinical milestones, in addition to single digit royalties.
Under the license, Sanofi will develop and commercialise an oral therapy for the treatment of inflammatory diseases, a multi-billion dollar market. The IL-17 family of cytokines are strong inducers of inflammation and are implicated in a variety of autoimmune diseases including psoriasis, psoriatic arthritis and ankylosing spondylitis. Current treatments targeting IL-17 are monoclonal antibodies administered via an injection. There is an urgent need for safe and efficacious oral small molecule therapies to increase the number of patients able to access IL-17 targeted drugs and expand availability into new inflammatory disease indications. C4XD’s small molecule IL-17A inhibitor programme can selectively block IL-17 activity in vivo whilst maintaining molecular size of the molecule in the traditional “drug-like” range suitable for oral administration. Sanofi will continue to work with the C4XD team to access its unique and proprietary 4D Conformetrix technology, as the programme advances towards clinical studies.
Clive Dix, CEO of C4X Discovery, said: “We are proud to be working with Sanofi to create much needed oral therapies in the underserved inflammatory disease space. While antibody therapies have demonstrated the potential of IL-17 inhibition in the generation of highly effective treatments, the injectable route means many patients currently do not have access to the medicines that can change their lives. We believe that our small molecule programme has the potential to create high value, efficacious and convenient oral IL-17 therapeutics for this large market. The Psoriasis market alone is estimated to be worth c.$24 billion per annum by 20271, and when combined with Sanofi’s development expertise our programme has the potential to address a number of indications.
At least 25p is my expectation for the end of the month.
Health / Markets January 03 2024 Michael Taylor
Astra Zeneca payment lifts C4XD just as it hits rock bottom
Drugs giant Astra Zeneca has paid Manchester-based pharma research business C4X Discovery US$11 million triggered by preclinical progress of C4XD’s treatment programme for inflammatory and respiratory diseases.
Under the terms of the licensing agreement announced in November 2022, AIM listed C4XD received an initial $2 million upfront payment and is potentially entitled to receive up to $400 million in preclinical, clinical development and commercial milestones, and to tiered mid-single digit royalties on future sales.
AstraZeneca is developing C4XD’s former NRF2 Activator programme to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic respiratory disease.
Dr Clive Dix
Clive Dix, chief executive of C4X Discovery, said: “This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation.
“We believe that our unique approach can deliver transformative oral therapies for patients suffering from immuno-inflammatory diseases. This is a great start to our year and we are confident of seeing further progress across our entire portfolio in 2024.”
The payment appears to vindicate an optimistic statement in December 2023 when Dix announced a drop in annual revenues and a deepening in pre-tax losses for the year to July 31, 2023, with just £1.71m coming in, causing losses of £13.416m.
Analysts at Panmure Gordon – also their nominated advisers – also issued a BUY note on the company as shares languished at an all time low of 8p, citing “ongoing income likely from its out-licensed programmes”.
C4XD is not a one trick pony...plenty more to come here
Clive Dix, CEO of C4X Discovery, said: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation. We believe that our unique approach can deliver transformative oral therapies for patients suffering from immuno-inflammatory diseases. This is a great start to our year and we are confident of seeing further progress across our entire portfolio in 2024."
15 Dec I posted
Well fwiw I am calling the bottom on these now.
Bring on the buyers and milestone payments which will be significant in Q1 2024.
I can wait and have the patience to outlast the short term girations here.
Good Luck to all genuine investors here for 2024.
Not a bad start of the year at all! Well done.
Lovely. So cash and assets near double mcap. But when quiet as I banged on about. Well done those adding at the silly prices. Nice to see a U.K. pharma constantly deliver now
Surely back to 20p and beyond with this milestone payment. Well done C4xd.
Have as much cash if not more, than our present valuation atm !!!
Boom...well, we know why this was shorted now....those in the know always get the cream
Will slowly build here. Could be telling that no director buys occurred as they could be in closed period with milestone payment very close as mentioned couple weeks back.